Lucira Health Inc represents key values such as innovation, efficiency, and quality in the healthcare industry. The company aims to revolutionize healthcare by developing convenient and accessible diagnostic solutions. With a focus on empowering individuals to take charge of their health, Lucira Health Inc has a strong corporate philosophy centered around enhancing patient outcomes and improving overall well-being. By leveraging cutting-edge technology and expertise, Lucira Health Inc strives to provide accurate and timely diagnostic tools that can be easily used at home or in point-of-care settings.

Lucira Health Inc is primarily present in the United States.

Lucira Health Inc has achieved several significant milestones. Firstly, in November 2020, the company received Emergency Use Authorization (EUA) from the FDA for its COVID-19 All-In-One Test Kit, becoming the first prescription, at-home molecular diagnostic test for COVID-19. This milestone marked a breakthrough in accessible and accurate testing during the pandemic. Additionally, Lucira Health Inc expanded its distribution partnership with the global pharmaceutical company, GlaxoSmithKline, in March 2021. This collaboration aimed to increase the availability of Lucira's COVID-19 at-home test kits in the United States. These milestones highlight Lucira Health Inc's commitment to innovative, convenient, and reliable diagnostic solutions.

Lucira Health Inc is a leading healthcare company specializing in providing innovative, accessible, and reliable diagnostic testing solutions. Established in [year], Lucira Health has a strong emphasis on developing rapid molecular diagnostic tests for various infectious diseases. The company's commitment to revolutionizing healthcare has resulted in the development of its FDA-authorized Lucira™ COVID-19 All-In-One Test Kit, which offers individuals the convenience of at-home testing. Lucira Health's groundbreaking technology aims to improve patient outcomes and access to accurate diagnostics. With a focus on delivering efficient and reliable solutions, Lucira Health continues to make strides in the field of healthcare diagnostics.

The main competitors of Lucira Health Inc in the market include companies like Abbott Laboratories, Quidel Corporation, and Becton, Dickinson and Company (BD).

Lucira Health Inc is primarily active in the healthcare industry.

The business model of Lucira Health Inc. revolves around providing accessible and convenient diagnostic testing solutions. Lucira Health Inc. specializes in developing and manufacturing innovative at-home rapid molecular testing platforms for various infectious diseases, including COVID-19. Through their proprietary technologies, Lucira Health Inc. enables individuals to easily detect and monitor their health conditions in the comfort of their own homes. Their user-friendly testing kits deliver accurate results within a short timeframe, promoting early intervention and timely treatment. Lucira Health Inc.'s business model aims to empower individuals, healthcare providers, and public health agencies by offering reliable and cost-effective testing solutions.

Lucira Health에 대한 현재 주가 수익 비율을 계산할 수 없습니다.

Lucira Health에 대한 현재 KUV는 계산할 수 없습니다.

Lucira Health에 대한 AlleAktien 품질 점수는 2/10입니다.

Lucira Health에 대한 현재 매출은 계산할 수 없습니다.

Lucira Health의 현재 이익을 계산할 수 없습니다.

Lucira Health Inc is a US-based company that offers medical devices and solutions in the field of in-vitro diagnostics. The company focuses on the needs of consumers and healthcare facilities and provides innovative solutions for conducting tests for various diseases and conditions quickly, easily, and reliably. Their business model encompasses the development, manufacturing, and marketing of diagnostic and monitoring solutions for a wide range of medical conditions, including HIV, hepatitis, and COVID-19. Their main product is a home-use COVID-19 test kit, which was approved by the FDA in November 2020. They also offer other products, such as a home-use rapid influenza test, as well as diagnostic solutions for hemoglobin, bilirubin, and glucose. Lucira Health Inc markets and distributes its products through various channels, including direct sales to healthcare facilities and online marketplaces like Amazon and Walmart. They have also signed an agreement with Grifols, a leading biotechnology company, to distribute their products in Europe and Latin America. The company collaborates closely with clinical partners and research institutions to develop and improve their products and solutions. Lucira Health Inc is well-positioned to grow and thrive in the in-vitro diagnostics market, thanks to its emphasis on collaboration and innovation.

Lucira Health은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Lucira Health의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Lucira Health의 ISIN은 US54948U1051입니다.

Lucira Health의 티커는 LHDXQ입니다.

지난 12개월 동안 Lucira Health은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Lucira Health은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Lucira Health의 현재 배당 수익률은 입니다.

Lucira Health은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Lucira Health은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Lucira Health은 '건강' 섹터에 속합니다.

Lucira Health의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Lucira Health는 0 USD를 배당금으로 지급했습니다.

Lucira Health의 배당금은 USD에 지급됩니다.